Abcam, ab142151, Everolimus, mTOR inhibitor

Size: 5mg / 25mg
MW 958.2 Da, Purity >98%. Potent mTOR inhibitor (IC 50 = 1.6 - 2.4 nM). Immunosupressant and anticancer activity in vivo . Orally active.
Key facts
CAS number:159351-69-6,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:958.2 Da,
Molecular formula:C53H83NO14,
PubChem:6442177,
Nature:Synthetic,
Solubility:Soluble in DMSO to 25 mM,
Biochemical name:Everolimus,
Biological description:Potent mTOR inhibitor (IC50 = 1.6 - 2.4 nM). Immunosupressant and anticancer activity in vivo. Orally active.,
Canonical smiles:CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,
Isomeric smiles:C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC,
InChi:InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1,
InChiKey:HKVAMNSJSFKALM-GKUWKFKPSA-N,
IUPAC Name:(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called 1917 Everolimus. 1917-25 is the same size as the 25 mg size of ab142151.

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target mTOR (mechanistic target of rapamycin) also known as FRAP1 is a serine/threonine kinase with a large molecular mass of approximately 289 kDa. It operates as a central regulator of cell growth proliferation and survival. mTOR is expressed ubiquitously in various tissues throughout the body participating in numerous cellular processes. Everolimus a derivative of rapamycin acts as a potent mTOR inhibitor. The chemical structure of everolimus contributes to its ability to specifically bind and inhibit mTOR activity demonstrating excellent solubility and effective inhibition within cellular environments.
Biological function summary
MTOR plays an important role in nutrient and energy signaling. It forms the core component of two distinct complexes mTORC1 and mTORC2 which regulate different cellular processes. mTORC1 controls protein synthesis and autophagy whereas mTORC2 is involved in cytoskeletal organization and cell survival. Everolimus inhibits mTORC1 affecting the protein synthesis machinery and therefore controlling cell growth and proliferation. It is this specific mechanism of action that highlights the therapeutic potential of mTOR inhibitors like everolimus.
Pathways
MTOR integrates signals from the PI3K/AKT and MAPK pathways. Through these pathways mTOR coordinates responses to growth factors nutrients and cellular energy status. mTOR is closely related to other signaling molecules like AKT and RHEB which modulate its activity. The PI3K/AKT pathway in particular is significant because it links mTOR's role in controlling protein synthesis and cell survival to external cellular signals illustrating the pivotal position mTOR holds in cell metabolism and growth pathways.
Alterations in mTOR signaling have been linked to cancer and neurodegenerative diseases. Dysregulation of mTOR activity can contribute to uncontrolled cell proliferation in cancer while in neurodegenerative diseases it may affect neuronal survival. Everolimus by inhibiting mTOR is employed in therapeutic interventions for certain cancers by targeting aberrant growth signals. The protein is also connected to p53 an important regulator of cell cycle and apoptosis suggesting its involvement in cellular stress responses associated with these diseases.